Preeclampsia Postpartum Antihypertensive Treatment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

Also called NCT04298034

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04298034
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04298034. Randomized; single masking; primary purpose treatment. Start 2020-07-17 (actual); primary completion 2025-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Preeclampsia Postpartum Antihypertensive Treatment
Acronym
P-PAT
Condition
Preeclampsia
Condition
Hypertension in Pregnancy
Intervention (Drug)
Labetalol, Nifedipine
Lead sponsor
Medical College of Wisconsin (class: other)

Record details

Record id
cardio:ct-nct04298034
Content hash
f058d39cd73737c0769e291cdba0a05ae34a56cbac1df3453e72c9af05b5d050